A St. Louis Hearing with Nationwide Reach
A Missouri judge on Monday, Sept. 14, will begin weighing final approval of a $7.25 billion settlement that would resolve most current and future lawsuits claiming Roundup weedkiller caused non-Hodgkin lymphoma. Judge Timothy Boyer of the Circuit Court of the City of St. Louis is not expected to rule immediately at the hearing, Reuters reported. The hearing was originally set for Aug. 19.
The deal reaches well beyond people who have sued. The court-authorized settlement website says it covers people exposed to Roundup products in the United States before Feb. 17, 2026, and warns that it "will affect you even if you have not been diagnosed with cancer."
That turns a courtroom fight into a household question for farmers, landscapers, groundskeepers, and homeowners who sprayed the product for years. If the court approves the deal, class members who later develop lymphoma would generally seek payment through a claims program rather than a lawsuit. The deadline to opt out passed on June 4.
Payment Tiers and Who Qualifies
Bayer faces roughly 65,000 claims in state and federal courts, according to Reuters, and the settlement aims to resolve nearly all current and future U.S. claims. The official site lists potential awards from $6,000 to more than $165,000, while Reuters described payouts of $10,000 to $165,000 for people with non-Hodgkin lymphoma. Amounts depend on factors such as disease severity, age at diagnosis, and whether exposure happened at home or at work. Monsanto would make declining, capped annual payments for up to 21 years, and it kept the right to end the deal if too many people opted out.
People already diagnosed would have 180 days after final approval to register. Those diagnosed later would not need to register now. According to the site, they would file a claim within six years of diagnosis or before the program's 16th annual payment date.
Monsanto announced the proposal on Feb. 17, and the court granted preliminary approval on March 4. An earlier settlement in 2020, worth about $10 billion, resolved many existing lawsuits but left Bayer exposed to future claims, Reuters noted.
Supporters say the deal guarantees compensation at a time when the legal landscape has shifted. On June 25, the U.S. Supreme Court ruled 7 to 2 that federal pesticide law bars state lawsuits claiming Monsanto failed to include a cancer warning on Roundup labels, CBS News reported.
Attorney Christopher Seeger, who would represent current claimants, said when the deal was announced that it was designed so today's and tomorrow's patients "have access to meaningful compensation," according to the Associated Press.
Critics disagree. Attorney Matt Clement, who represents about 280 plaintiffs, told the AP the proposed payouts "are exceedingly too small." Opponents also argue that the deal traps future claimants who would prefer to go to court. A Monsanto spokesman told Reuters the company believes the settlement "is fair to all parties and warrants final approval."
A Legal Deal, Not a Scientific Verdict
The settlement does not answer the medical question. In 2015, the World Health Organization's International Agency for Research on Cancer classified glyphosate, Roundup's key ingredient, as probably carcinogenic to humans. The U.S. Environmental Protection Agency found in 2017 that glyphosate was not likely to cause cancer in humans at expected real-world exposures, and the agency expects to finish an updated human health risk assessment in late 2026. The EPA does not require a cancer warning on Roundup's label.
Research has produced mixed signals. A large National Cancer Institute-supported study of pesticide applicators, published in 2018, found no overall link between glyphosate and non-Hodgkin lymphoma, while some later pooled analyses suggested higher risk among the most heavily exposed workers. Bayer denies that glyphosate causes cancer, and the settlement includes no admission of liability.
For readers, the key point is that a payment would not be a finding that Roundup caused any individual's cancer. It reflects legal risk on both sides.
Because of the lawsuits, Bayer has already stopped using glyphosate in Roundup sold for U.S. residential lawns and gardens, the AP reported. Glyphosate remains widely used in agriculture.
Practical Moves for Exposed Workers and Families
Non-Hodgkin lymphoma is a cancer of the lymphatic system. Warning signs can include painless swelling of lymph nodes in the neck, armpit, or groin; unexplained fever; drenching night sweats; weight loss; and persistent fatigue. These symptoms have many causes, but anyone who notices them for more than a few weeks should see a clinician. Trouble breathing, severe chest pain, or rapidly worsening symptoms need urgent care.
Farmworkers, landscapers, and groundskeepers with years of heavy herbicide use have the greatest exposure. Anyone who handles weedkillers can limit contact by following label directions, wearing gloves and long sleeves, and washing skin and clothing after spraying.
People who think they may be class members can sign up for updates through the official site. Registration and claims will not open unless the court grants final approval, and the settlement administrator, BrownGreer, would handle them. Keeping records of diagnosis dates, exposure history, and treatment can make a future claim easier. People with a new lymphoma diagnosis can also ask their oncologist about the specific subtype, since treatment and outlook vary widely across the many forms of non-Hodgkin lymphoma.
Readers should be cautious of advertising that promises specific payouts. The court-authorized website and its administrator are the official sources for eligibility information. Settlement payments are also separate from medical care, so anyone with symptoms should not wait for the court process to seek an evaluation.
What happens next rests with Judge Boyer, who is not expected to rule at the hearing itself, and any approval could face appeals that delay payments. The deal would cover far more people than current plaintiffs, the science remains disputed, and anyone with persistent lymphoma warning signs should get checked regardless of what the court decides.
Key Questions Answered
What is happening Monday?
A judge in St. Louis will hold a fairness hearing on whether to grant final approval to Monsanto's proposed $7.25 billion Roundup class settlement. No immediate ruling is expected.
Who is covered by the settlement?
People exposed to Roundup products in the U.S. before Feb. 17, 2026, including those who have not been diagnosed with non-Hodgkin lymphoma, unless they opted out.
How much could people receive?
The official site lists awards from $6,000 to more than $165,000, depending on factors such as disease severity, age at diagnosis, and type of exposure.
Can I still opt out?
No. The deadline to opt out and keep the right to sue individually was June 4, 2026, according to the official settlement website.
Does the settlement prove Roundup causes cancer?
No. Bayer denies that glyphosate causes cancer, and scientific agencies have reached different conclusions. A settlement payment is not a medical finding.
What lymphoma symptoms should people watch for?
Painless swollen lymph nodes, unexplained fever, drenching night sweats, weight loss, and persistent fatigue lasting more than a few weeks should be checked by a clinician.
When could payments begin?
Not until after final approval and any appeals are resolved. Diagnosed class members would have 180 days after final approval to register.
